On May 30, 2019 Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, reported that it will present data and exhibit at the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 31 to June 4, 2019, at the McCormick Place Convention Center in Chicago, Illinois (Press release, Athenex, MAY 30, 2019, View Source;p=RssLanding&cat=news&id=2400079 [SID1234536687]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Athenex will introduce its new brand established for the oncology platform, Athenex Oncology, at its exhibition booth (#4150) at ASCO (Free ASCO Whitepaper) 2019 (exhibition dates: June 1 to 3, 2019), which will also showcase the potential of the Orascovery Platform and latest development pipeline.
Athenex has four abstracts accepted for poster presentation and two abstracts accepted for online publication only.
Details of Poster Presentations:
Title: (Abstract TPS1116) KX-ORAX-001: An open label, randomized, multicenter, Phase III registrational study to determine the safety, tolerability, and tumor response of Oraxol (HM30181A + oral paclitaxel) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC).
Presenter: Gerardo Antonio Umanzor Funez, DEMEDICA, San Pedro Sula, Honduras
Poster Session: Breast Cancer—Metastatic
Session Date, Time, Location: Sunday, June 2, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.
Title: (Abstract 1084) Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients.
Presenter: Ming-Shen Dai, Tri-Service General Hospital, Taipei, Taiwan
Poster Session: Breast Cancer—Metastatic
Session Date, Time, Location: Sunday, June 2, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.
Title: (Abstract 3032) A Phase 1 study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A.
Presenter: Antonio Jimeno, University of Colorado, Aurora, CO
Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Session Date, Time, Location: Saturday, June 1, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.
Title: (Abstract 3090) Design, engineering, and characterization of a novel long-acting (Pegylated) single isomer human arginase for arginine depriving anti-cancer treatment.
Presenter: Kuo-Ming Yu, Athenex, Inc., Buffalo, NY
Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Session Date, Time, Location: Saturday, June 1, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.
Abstracts Accepted for Online Publication Only:
Title: (Abstract e15518) A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy.
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.
Title: (Abstract e12577) Eribulin ORA: A novel oral formulation of eribulin based on combination with
the P-gp inhibitor HM30181A.
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.
The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery